Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(3.42) per share which missed the analyst consensus estimate of $(0.95) by 260 percent. This is a 575 percent decrease over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $744.86 million which beat the analyst consensus estimate of $683.36 million by 9.00 percent. This is a 80.15 percent increase over sales of $413.46 million the same period last year.